CoChat

Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database

Open access

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). Methods: This retrospective pharmacovigilance study used the US FDA FAERS database (2007–2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. Results: From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC025: 0.151, βCoeff: 0.314), vomiting (IC025: 0.334, βCoeff: 0.495), and delayed gastric emptying (IC025: 0.342, βCoeff: 0.453). Exenatide was associated with pancreatitis (IC025: 0.601, βCoeff: 0.851) and death (ROR: 4.50, IC025: 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Conclusions: Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics14242829

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The flow diagram of selection of GLP-1 RA-associated adverse events and outcomes from the FAERS database.
Figure 1 The flow diagram of selection of GLP-1 RA-associated adverse events and outcomes from the FAERS database.CC BY · PubMed Central
Figure 2 Proportion of gastrointestinal adverse effects reported with different GLP-1 RAs. GERD: gastroesophageal reflux disease; IBD: inflammatory bowel disease.
Figure 2 Proportion of gastrointestinal adverse effects reported with different GLP-1 RAs. GERD: gastroesophageal reflux disease; IBD: inflammatory bowel disease.CC BY · PubMed Central
Figure 3 Safety signals of gastrointestinal adverse events and adverse outcomes associated with GLP-1 RAs. ROR: reporting odds ratio; GI: gastrointestinal; GLP-1 RAs: glucagon-like peptide-1 receptor agonists.
Figure 3 Safety signals of gastrointestinal adverse events and adverse outcomes associated with GLP-1 RAs. ROR: reporting odds ratio; GI: gastrointestinal; GLP-1 RAs: glucagon-like peptide-1 receptor agonists.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

Metadata

Authors
Osei, S. P., Akomaning, E., Florut, T. F., Sodhi, M., Lacy, B. E., Aldhaleei, W. A., & Bhagavathula, A. S.
Affiliations
  • North Dakota State University (US)
  • Simon Fraser University (CA)
  • University of British Columbia (CA)
  • Mayo Clinic (US)
Corresponding author
Bhagavathula, Akshaya Srikanth
Venue
Diagnostics
Publisher
MDPI AG
Published
2024-12-16
Volume
14
Issue
24
Pages
2829
ISSN
2075-4418 (ISSN-L)
OpenAlex
W4405445936
Cited by
38
References
19
Citations by year
2026: 24 · 2025: 14
FWCI
9.04
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • cIRcle (University of British Columbia) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Open Collections
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, gastrointestinal adverse effects, semaglutide, exenatide, dulaglutide, liraglutide, nausea, vomiting, delayed gastric emptying, pancreatitis, drug safety, pharmacovigilance, adverse event reporting, obesity, diabetes mellitus, FDA Adverse Event Reporting System, safety signals, reporting odds ratio, proportional reporting ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.